MedTrace Logo

CSF Proteomic Characterization of Glioblastomas

NCT06845020 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2025-02-25

No results posted yet for this study

Summary

The goal of this observational study is to identify proteins that can be found in the cerebrospinal fluid (CSF) of patients with grade IV brain tumors, specifically glioblastomas, and correlate these proteins with progression free survival, overall survival and performance status (functionality). All participants with high probability of glioblastoma will initially be included, final inclusion will be dependent on the definitive histopathological diagnosis of the tumor.

The main question is:

Can the researchers identify a proteomic profile in CSF from study participants with glioblastoma in association with a longer progression free survival? Participants will undergo the following procedures, that do not deviate from normal standard diagnostic care.

1. Lumbar puncture to obtain CSF.
2. Blood draw.
3. Trans-surgical tissue sample of the brain tumor. Additionally participants will be planned for follow up appointments every 3 months following the first 12 months after the surgical tumor resection.

Conditions

  • Glioblastoma
  • Glioblastoma WHO Grade IV
  • Glioblastoma (GBM)
  • Glioblastoma Multiforme of the Brain
  • Glioblastoma, Adult

Sponsors & Collaborators

  • Mayo Clinic

    collaborator OTHER

  • Hospital Valentin Gomez Farias

    collaborator OTHER

  • Univeridad Autonoma de Guadalajara

    lead OTHER

Principal Investigators

  • Maria Guadalupe Zavala Cerna, MD, PhD · Universidad Autónoma de Guadalajara

  • Hugo Guerrero Cazares, MD, PhD · Mayo Clinic Jacksonville, Florida.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2027-02-28
Completion
2028-03-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06845020 on ClinicalTrials.gov